Attorney's Docket No.: 09010-004005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Murphy, et al.

Art Unit : 1652

Serial No.: 09/886,400

Examiner: Delia M. Ramirez, Ph.D.

Filed

: June 20, 2001

Title

SEP 3 0 2003
TECH CENTER TOUL, 2300 : ALPHA GALACTOSIDASES AND METHODS FOR MAKING AND USIN

THEM (AMENDED)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed for filing in the above-referenced patent application is a Form PTO-1449. This supplemental statement is being filed with a Request for Continued Examination in response to the Office Action dated March 26, 2003. Applicants respectfully request consideration of the remarks and references set forth herein.

The following documents are enclosed herewith:

- copy of Form PTO-1449
- Postcard
- copies of cited references

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or Printed Name of Person Signing Certificate

Attorney's Docket No.: 09010-004005

Applicant: Murphy, et al. Serial No.: 09/886,400 : June 20, 2001 Filed

: 2 of 2 Page

## REMARKS

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

This submission is a supplemental Information Disclosure Statement (IDS). The previous IDS and PTO FORMs 1449 were submitted on October 14, 2002 and January 24, 2003.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 06-1050. If necessary, please deduct any necessary additional fees from, or credit any overpayment to, the above-noted Deposit Account.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 858 678 5070.

Respectfully submitted,

Gregory P. Einhorn

Reg. No. 38,440

Fish & Richardson P.C.

4350 La Jolla Village Drive, Suite 500

San Diego, California 92122 Telephone: (858) 678-5070 Facsimile: (858) 678-5099

10321226.doc

						Sile	u <u> </u>	
	Substitute Form PTO-1449	U.S. Department	artment of Commerce and Trademark Office	Attorney's Docket No. 09010-004005		Application No. 09/886,400	RECEN	
	formation	Disclosure Sta y Applicant	tement	Applicant Murphy, et al.		- IFOI	SEPSIVE	7
BE SE	2 9 7003 V (Use seve	ral sheets if necess	ary)	Filing Date June 20, 2001		Group Act of the 1652	ENTER 16003	
BATERLY	(37 CFR §1(\$8(b))	Documents			Filing Date			
	Examiner Desig.	Document Number	Publication Date	Patentee	Class	Subclass	If Appropriate	

ADISABEIS			U.S. Pate	ent Documents			Filing Date
Examiner Initial	Desig.	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
mittai	AA	6,057,098	May 2, 2000	Buechler et al.			
	AB						
	AC						
	AD						
	AE			ļ			
	AF				-		
	AG						<del> </del>
	AH					<u> </u>	

				blished Foreign	Patent A	pplication	าร	
	Foreigr	n Patent Doc	uments or Pu	blished Foreign Country or			Trans	lation
Examiner Initial	Desig. ID	Document Number	Publication Date	Patent Office	Class	Subclass	Yes	No
	AI							
	AJ							
	AK							
	AL				_		<del> </del>	
	AM						<u> </u>	L

	Other Do	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig.	Document  Document  A : A Substitutions Outside an Antigenic Site on Protein Binding to
	AN	Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies of Predetermined Specificity Obtained by Topate and Monoclonal Antibodies and Monoclonal Ant
	AO	Ngo, et al., "Computational Complexity, Protein Structure Prediction, Chapter 14, pp. 491-494
	AP	The Protein Folding Problem and Ternary Structure Treatestors, enspersions, Elsevier Science  Campbell, "General Properties and Applications of monoclonal antibodies", Elsevier Science  Publishers, section 1.1., pp. 1-32, 1984
	AQ	Publishers, section 1.1., pp. 1-32, 1984  Li, et al., "β-endorphin omission analogs: Dissociation of immunoreactivity from other biological activities", Proc. Natl. Acad. Sci., Vol. 77, No. 6, pp. 3211-3214, June, 1980  Lederman, et al., "A Single Amino Acid Substitution in a Common African Allele of the CD4  Lederman, et al., "A Single Amino Acid Substitution in A Common African Allele of the CD4
	AR	Lederman, et al., "A Single Amino Acid Substitution in a Common American Molecule Ablates Binding of the Monoclonal Antibody, OKT4, Mol. Immunology, Vol. 28, No. 11, pp. 1171-1181, 1991

L		
		Date Considered
ſ	Examiner Signature	
۱		
١	EXAMINER: Initials citation considered. Draw line through citation if no	the state of Include copy of this form with
Į	Draw line through citation if no	ot in conformance and not considered. Include copy of the form
	EXAMINER: Initials citation considered. Draw line through statement	
Ì	next communication to applicant.	Substitute Disclosure Form (PTO-1449)
IJ	TICKE CONTINUE TO THE TENT OF	

Substitute Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 09010-004005	Application No. 09/886,400	
by Applicant (Use several sheets if necessary)		Applicant Murphy, et al.		
		Filing Date June 20, 2001	Group Art Unit 1652	

BADENECIE	Other Do	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document Percerah in
	AS	Colman, "Effects of amino acid sequence changes on antibody-antigen interactions", Research in Immunology, Vol. 145, No. 1, pp. 33-36, 1994
	AT	Koizumi, et al., "Isolation and characterization of novel heterogenous branched cyclomalto- oligosaccharides (cyclodextrins) produced by transgalactosylation with a-galactosidasse from coffee heap." Carbohydrate Research, Vol. 278, pp. 129-142, 1995
	AU	Witkowski, et al., "Conversion of Beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine", <u>Biochemistry</u> , Vol. 28, pp. 11643-1160, 1999
	AV	Ishii, et al., "Human α-galactosidase gene expression: significance of two peptide regions encoded by exons 1-2 and 6", <u>Biochimica et Biophysica Acta</u> , Vol. 1204, pp. 365-270, 1994

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	ot in conformance and not considered. Include copy of this form with

next communication to applicant.